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A B S T R A C T
Glucarpidase, also known as carboxypeptidase G2, is a Food and Drug Administration-approved enzyme used in
targeted cancer strategies such as antibody-directed enzyme prodrug therapy (ADEPT). It is also used in drug
detoxification when cancer patients have excessive levels of the anti-cancer agent methotrexate. The application
of glucarpidase is limited by its potential immunogenicity and limited catalytic efficiency. To overcome these
pitfalls, mutagenesis was applied to the glucarpidase gene of Pseudomonas sp. strain RS-16 to isolate three novels
“biobetter” variants with higher specific enzyme activity. DNA sequence analysis of the genes for the variants
showed that each had a single point mutation, resulting in the amino acid substitutions: I100 T, G123S and
T239 A. Km, Vmax and Kcat measurements confirmed that each variant had increased catalytic efficiency relative
to wild type glucarpidase.
Additionally, circular dichroism studies indicated that they had a higher alpha-helical content relative to the
wild type enzyme. However, three different software packages predicted that they had reduced protein stability,
which is consistent with having higher activities as a tradeoff. The novel glucarpidase variants presented in this
work could pave the way for more efficient drug detoxification and might allow dose escalation during che-
motherapy. They also have the potential to increase the efficiency of ADEPT and to reduce the number of
treatment cycles, thereby reducing the risk that patients will develop antibodies to glucarpidase.
1. Introduction
Several strategies for targeted cancer therapy involving glucarpi-
dase, also known as Carboxypeptidase G2 (CPG2), have been put into
clinical practice in recent years [1]. (Glucarpidase or CPG2 will be used
interchangeably throughout the text).
Glucarpidase has proved particularly useful in Antibody Directed
Enzyme Prodrug Therapy (ADEPT), in which it accumulates at the site
of a tumor via a tumor-specific antibody, after that it converts a prodrug
into an active drug [2–4].
In contrast, in cases of methotrexate-induced toxicity, glucarpidase
is administered to convert this anti-cancer agent to a less harmful
compound (4-deoxy-4-amino-N10-methylpteroic acid) that is excreted
via a hepatic pathway. The enzyme is typically given in high doses to
patients, thereby decreasing the risk of renal failure [5–9].
Although clinically useful, patients treated with glucarpidase often
develop antibodies against it, which limits the number of times it can be
administered.
Additionally, the wild-type enzyme has limited catalytic efficiency
and hence must be given in relatively high doses. For both reasons, it
would be desirable to develop variants of CPG2 that have increased
specific activity but different immunogenic properties due to their al-
tered structures. Such variants might escape recognition by the patients’
immune system and might also allow clinicians to decrease the amount
of CPG2 that is administered.
The re-assortment of mutations to produce favorable combinations
that can undergo natural selection is a critical component of biological
evolution. This process can be simulated by directed evolution, which
has proved to be an effective strategy for improving or altering the
activity of biomolecules for industrial, research and therapeutic
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applications. The evolution of proteins in the laboratory uses error-
prone DNA replication in vitro to generate genetic diversity and specific
screens to identify protein variants with desired properties [10]. Where
necessary, the genes for these variants can then be shuffled in a process
akin to homologous recombination to achieve further improvements
[10]. In several instances, chimeric enzymes with improved activity and
stability have been isolated from libraries constructed using DNA
shuffling [11–14]. In other cases, the method resulted in libraries with
either too many mutations in each gene [15] or too few crossovers [16]
to be useful.
DNA shuffling can take advantage of orthologous proteins to re-
purpose functional diversity from nature, i.e. in addition to using error-
prone replication in vitro, it can be used to shuffle distantly related
existing sequences to take advantage of the natural diversity that exists
within a population and to provide a means to eliminate deleterious
mutations that may accumulate in strains [17]. On the other hand, it is
limited by the degree of sequence homology shared by the existing
sequence variants [10].
This paper describes the production of novel CPG2 variants with
increased activity, which may also have structural alterations, and
hence altered immunogenicity, thereby allowing additional cycles of
therapy. The novel highly active glucarpidase(s) were sub-cloned,
overexpressed and functionally characterized.
2. Materials and methods
2.1. Growth media, enzymes, chemicals and antibodies
LB Media was from Formedium (Norfolk, UK) and where necessary
was solidified with 1.5% (w/v) Bacto-agar (Fermentas; Waltham,
Massachusetts, USA). Enzymes for cloning and expression of the glu-
carpidase genes were purchased from Thermo Scientific, with the ex-
ception of Sau3AI, BamH1 and a PCR master mix (2×) kit, which was
purchased from Promega (Fitchburg, Wisconsin, USA). Ni-NTA resin
was purchased from Sigma-Aldrich (Saint Louis, Missouri, USA).
GilPilot 1 kb DNA ladder (100) was purchased from Thermo Scientific
(Waltham, Massachusetts, USA), Wizard® SV Gel and PCR Clean-Up
System Kit were purchased from Promega. GeneJET Plasmid Miniprep
Kit was obtained from Thermo Scientific. All other chemicals were of a
high analytical grade. The mass spectroscopy (MS) analysis was carried
out at the Toxicology and Multipurpose Labs, ADL-Qatar. Anti-Xen
CPG2 Polyclonal Antibodies were produced by Eurogentec, Belgium,
anti-Rabbit IgG (whole molecule)–Peroxidase antibody produced in
goat (Sigma-Aldrich) was used as secondary conjugated antibody. 6×
His Epitope Tag Antibody (HIS. H8) (Thermo Scientific) was used for
detection of the purified 6-His-tagged CPG2 and Polyclonal Rabbit Anti-
Mouse Immunoglobulins/HRP (Dako Labs, Santa Clara, California,
USA) was used as the secondary antibody.
2.2. Mutagenesis and recombination by DNA shuffling
DNA shuffling was carried out essentially according to the Stemmer
method [18] using as a template a synthetic version of the CPG2/glu-
carpidase gene from Pseudomonas putida that had been codon-optimized
for expression in E. coli [19]. First, to enhance the natural mutation
rate, libraries of glucarpidase mutants were constructed by error-prone
PCR. 30 pmol of each primer flanking the glucarpidase gene set (CPGF;
5′-ACC GGA TCC CAT ATG GCG CTG GCC CAG AAA CG-3′, and CPGR
5-CTT AAG CTT TTA TTT GCC CGC ACC CAG ATC C-3′), 5 mM MgCl2,
0.2 mM of each dATP and dGTP, 1mM of each dTTP and dCTP, and
0.5 μl Taq polymerase was used in the PCR reactions. The thermal cy-
cling parameters were: 95 °C for 2min (1 cycle), 95 °C for 1min, 55 °C
for 1min, 72 °C for 2min (30 cycles) and 72 °C for 5min (1 cycle). The
PCR products were purified using a PCR purification kit (Thermo Sci-
entific). 44 μl of purified DNA template was then mixed with 2.5 μl of
1M Tris−HCl (pH 7.5), 2.5 μl of 200mM MnCl2 and brought to a final
volume of 49 μl with deionized water. The mixture was equilibrated at
15 °C for 5min. Subsequently, 1 μl DNase I (10 U/μl) diluted to 1:100 in
deionized water for digestion at 15 °C was added. Aliquots (10 μl) was
taken after 30 s, 1, 2, 3 and 5min of incubation and immediately mixed
with 5 μl of ice-cold stop buffer containing 50mM EDTA and 30% (v/v)
glycerol. Large scale DNase digest was carried out and the fragments
were separated by electrophoresis in 2% agarose gels and DNA frag-
ments in the 200-300bp size range were cut from the gel and extracted.
Then, a primerless PCR reaction was carried out, in which 10 μl of
purified fragments were combined with 5 μl of 10× Pfu buffer, 5 μl of
10× dNTP mixture (2mM of each dNTP) and 0.5 μl of Pfu polymerase
to a total volume of 50 μl and then PCR reaction was performed. PCR
conditions were: 1 cycle at 95 °C for 3min, 40 cycles of 95 °C for 30 s,
55 °C for 1min, 72 °C for 1min+5 (s per cycle) and 72 °C for 5min (1
cycle). Recombinant genes were amplified in a standard PCR reaction
using serial dilutions of the assembly reaction. The PCR reaction con-
ditions were: 1 μl serial diluted templates, 10 pmol of each primer set,
5 μl of 10× Pfu buffer, 1 μl of 10× dNTP mixture (2mM of each dNTP)
and 0.5 μl of Pfu polymerase in the total volume of 50 μl. The thermal
cycling parameters was 95 °C for 2min (1 cycle), 95 °C for 1min, 55 °C
for 1min, 72 °C for 2min (30 cycles) and 72 °C for 5min (1 cycle).
2.3. Sub-cloning of shuffled glucarpidase (S-glucarpidase) mutants
The PCR products were purified using a gel extraction kit (Thermo
Scientific) and double-digested with the restriction enzymes NdeI and
HindIII. After further gel purification, the digested glucarpidase gene
fragments were ligated into the NdeI/HindIII sites of the pET28a ex-
pression vector and transformed into competent E. coli. Plasmid mini-
preps were purified and sequenced using T7 promoter and terminator
primers to screen for mutations.
2.4. Screening for functional S-glucarpidase(s)
Derivatives of the expression vector pET28a expression vector
containing variant genes for the shuffled glucarpidase (variants) were
selected, transformed into the expression host E. coli BL21(DE3) RIL,
and then plated on LB/agar plates containing 0.1mM isopropyl-β-D-
thiogalactopyranoside (IPTG), folate and the required antibiotics. The
plates were incubated at 37 °C overnight, and colonies that were sur-
rounded by clear zones were selected for protein expression and activity
assays using cell-free extracts, as previously described. [20] Priority
was given to colonies with large ‘halo zones’, on the assumption that
these either produced more glucarpidase or corresponded to variants
with increased enzymatic activity.
2.5. Recombinant protein expression and characterization
E. coli BL21(DE3) RIL cells contain pET28a-CPG2, or the same ex-
pression vector contain a variant, were incubated with shaking
(200 rpm) at 37 °C in 250ml of LB medium supplemented kanamycin
and chloramphenicol (both at 32 μg/ml) until the optical density at
600 nm reached 0.5-0.6. Induction of expression of recombinant CPG2
was initiated by the addition of IPTG at a final concentration of 1mM,
whereupon the culture was incubated for a further four hours at 37 °C
with shaking. Cells were collected by centrifugation at 4000 rpm for
20min at 4 °C and the pellets were re-suspended in Tris buffer (pH 7.5),
50mM NaCl. Lysis was achieved by sonication, using Soniprep 150
plus, on ice (5 cycles of 30 s sonication pulses followed by 1min rest).
The soluble fraction was separated by centrifugation at 14,000 rpm for
20min at 4 °C. The soluble and insoluble fractions were mixed with 2×
sample buffer, boiled for ten minutes at 95 °C, and then analyzed by
SDS-PAGE. Protein expression in cells incubated at 20 °C was carried
out identically to assess the effect of temperature on improving soluble
protein expression.
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2.6. Purification using nickel affinity chromatography
Protein extracts from E. coli BL21 (DE3) RIL cells containing
pET28a-CPG2, or the same expression vector containing a variant, were
subjected to purification by Ni2+ affinity chromatography using Ni-
NTA resin. About 1ml of the resin was washed with distilled water and
activated by binding and washing buffer A (20mM Tris pH 8, 50mM
NaCl, 5 mM β-mercaptoethanol (BME), and 20mM Imidazole) then the
total soluble protein was combined with the activated resin and gently
agitated for 20min at 4 °C to allow the protein to bind to the column
resin. The resin was separated by gravity, the flow-through was col-
lected, and the resin was washed 3 times with buffer A. The target
protein (bound to the resin) was collected by adding ice-cold elution
buffer B (20mM Tris pH 8, 50mM NaCl, 5 mM BME and 400mM
Imidazole). The eluted protein was dialyzed against 100mM Tris−HCl
pH 7.3 containing 0.2mM ZnSO4. All fractions from the protein pur-
ification were analyzed by SDS-PAGE. MTX hydrolysis the pure re-
combinant glucarpidase was assayed using as described below.
2.7. Assay of wild-type and mutant glucarpidase activity using methotrexate
The glucarpidase activity of each of the shuffled variants was de-
termined using MTX as substrate. The assay was a modification of the
method described by McCullough [21]. 0.1 M Tris−HCl (pH 7.3),
0.2 mM ZnSO4 was used as a dilution buffer for 5 μl of MTX (0.45 mM,
final concentration). After equilibration of the reaction mixture at 37oC
for 10min, a total protein extract from the expressed shuffled variant
(50 μg/ml) was added and incubated at 37oC. Samples were taken at
10min intervals, and the decrease in absorbance at 320 nm was mea-
sured using a NANODROP 1000 spectrophotometer (Thermo Scien-
tific). The same protocol was used to analyze the activity of the pure
recombinant CPG2 using 3 μg/ml protein. The Michaelis-Menten
equation was used for determination of the actual values of Km, Kcat,
and Vmax of each protein using GraphPad PRISM 6 software (San Diego,
California, USA). One unit of the enzyme represents the amount of
enzyme in mg required for hydrolysis of 1mM of MTX per min at 37 °C.
The enzyme activity per ml of protein was calculated using 8300 as the
molar extinction coefficient for MTX.
2.8. Circular dichroism of the shuffled CPG2
a Pre-CD Scanning
The wild-type CPG2 and the three variant proteins were purified
and dialyzed against Milli-Q water 4 times, 18 h each, then clarified by
centrifugation at 14,000 rpm for 30min at 4 °C. To measure the protein
concentration a NanoDrop 2000 spectrophotometer (Thermo Scientific)
was used to achieve the required concentration of about 6 μM for the
CD measurement. The extinction coefficients were calculated as ε
24,870 M−1 cm−1 for the four proteins WT, CPG2I100 T, CPG2T329 A
and CPG2G123S.
• Circular Dichroism (CD)
CD measurements were obtained using a Chirascan™ Plus CD
Spectrometer (Applied Photophysics). Scanning of the proteins (6 μM,
final concentration) in the far UV spectral region (260 to 180 nm) was
performed in a rectangular demountable SUPRASIL Quartz cuvette
(Hellma®) of 0.2 mm light-path length (sample volume ∼70 μl). The
applied CD parameters were: bandwidth 1 nm and scan time per point
of 0.5 s at 20 °C. Four scans were taken per sample, and the readings
were averaged and smoothed using the CD analysis software. The
produced spectra were subtracted from an averaged CD spectra of the
blank baseline (Milli Q water).
• CD- deconvolution method
Protein secondary structures of the pure shuffled CPG2 were cal-
culated by CD data and the deconvolution analysis using the CDNN
(version 2.1) software tool. A spectral range of (180–260 nm) was used
for the deconvolution calculation. The number of residues and mole-
cular weight were taken as 394 AAs, with 41.9117, 41.8996, 41.8817,
41.9417 kDa for the WT, CPG2I100 T, CPG2T329 A and CPG2G123S,
respectively, and the light-path length of the cuvette used was 0.2 cm.
2.9. Prediction of the impact of the single point mutation on glucarpidase
To find a possible correlation with the results of the activity assays,
three software packages, mCSM [22], SDM [23], and DUET [24], were
used to predict the effects of the mutations on glucarpidase stability and
to generate environment-specific substitution tables (ESST) and ther-
modynamic stability data for glucarpidase mutants.
2.10. Prediction of Hydrogen bond networking of the mutants
The models were generated using Modeller package [25–28] from
the crystal structure of carboxypeptidase G2 (PDB: 1CG2). Polar con-
tacts are depicted in red dotted lines and the picture was rendered with
Pymol (Version 2.2 Schrödinger, LLC).
2.11. Statistical analysis
Data are presented as mean ± standard error of the mean (S.E.M)
of “3″ observations. All graphs were constructed using GraphPad Prism
6 software (San Diego, CA, USA). Statistical analysis was performed
using Student t-test or two-way ANOVA as appropriate. P values< 0.05
were considered statistically significant.
3. Results
3.1. Mutagenesis of the glucarpidase gene
Error-prone PCR was used to mutate the CPG2 gene of Pseudomonas
putida, which has previously been codon-optimised for expression in E.
coli [20]. The mutated genes were fragmented, and then primer-less and
conventional PCR was used in an attempt to produce shuffled DNA, and
to amplify full-length genes containing mutations (see Materials and
Methods for further details) (Supplemental Fig. S1). Following cloning
into the expression vector pET28a, DNA sequence analysis was used to
confirm mutation and shuffling of the CPG2 gene (data not shown).
3.2. Isolation of variants with enhanced CPG2 activity
pET28a plasmids containing CPG2 variants were transformed into
BL21(DE3)RIL and screened for glucarpidase activity on folate-con-
taining agar plates. Approximately four thousand colonies containing
variants were screened for hydrolysis of folate by searching for clear
zones and yellow precipitates around colonies. 73% of the four thou-
sand colonies grown on folate containing media plates formed clear
zones and, of this set, three colonies displayed a significantly darker
coloration after two days of incubation relative to cells harboring the
original pET28a-CPG2 construct (Supplemental Fig. S2). This suggested
that the isolates either produced more glucarpidase or that the glu-
carpidase in question had a higher level of activity against the folate
substrate.
The mutations in the CPG2 genes of three variants that were se-
lected for the further study were identified by sequencing
(Supplemental Fig. S3). Each mutant had a single but different codon
change relative to the wild-type CPG2 sequence, corresponding to the
following amino acid changes: C100 T, G123S, and T329 A.
Accordingly, the mutants were named CPG2I100 T, CPG2G123S, and
CPG2T329 A.
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3.3. Purification of the glucarpidase mutants and Western Blot analysis
The three mutant enzymes were overexpressed and purified by af-
finity chromatography using Ni columns. Fig. 1 shows a representative
purification for the wild-type and CPG2 I100 T mutant while Fig. 2
shows the corresponding Western blot analysis using an anti-His anti-
body.
3.4. Activity of mutant glucarpidases relative to the wild-type enzyme
Equal amounts of protein extracts containing the wild-type and
mutant CPG2 enzymes were assayed for glucarpidase activity using
MTX as a substrate in the presence of Zn2+ ions, as described in the
Materials and Methods section. The results indicated that each of the
mutants had a higher glucarpidase activity than the wild type enzyme
(Fig. 3). The I100 T and G123S mutants showed the largest increases in
enzyme activity. However, the T329 A mutant also had a significantly
increased activity relative to wild-type CPG2 but less activity than the
other two mutants.
Two-way ANOVA statistical analysis of the Enzyme Activity Assay
showed a significant difference in activity between the four enzymes
p < 0.001. When compared with the WTCPG2, there was a significant
difference in activity at time 60–780, 150–660 and 180–270 for
CPG2I100 T, CPG2G123S and CPG2T329 A, respectively. Details are
provided in the (Table 1).
3.5. Kinetic studies of the mutants and comparison with WT-CPG2
More detailed kinetic studies were carried out to characterize the
variants further. Specifically, the Km, Vmax and Kcat values for the
Fig. 1. Ni-NTA Protein purification of CPG2 (P.
putida and one of the shuffled variant, I100 T)
in Bl21(DE3)RIL. A. protein purification of P.
putida CPG2, and B. an example of a protein
purification of a mutant protein, where M is
SeeBlue Plus2 Pre-Stained Protein Standard
(3–198 kDa), lanes 1, 2, 3, 4, 5, and 6 are total
soluble, flow-through, wash, and elutions (E1,
E2, and E3 for CPG2 of P. putida) respectively.
Fig. 2. Western blotting analysis of the shuffled
CPG2s relative to WT-CPG2. A) Shows the re-
levant gel image after SDS-PAGE while B) the
corresponding immunoblot. Lanes 1, 2, 3 and 4
are WTCPG2, CPG2I100 T, CPG2T329 A and
CPG2G123S, respectively. C) Densitometric
quantification of bands was carried using
GASepo analysis software. Results are ex-
pressed as the percentage of WTCPG2 band
intensity and are presented as mean ±
standard error of the mean (S.E.M) of 3 in-
dependent experiments. Statistically significant
difference: *p < 0.05 and **p < 0.01 while
ns is not significant. Ex-#1, Ex-#2, and Ex-#3,
three independent western blot replicates are
shown in the supplement section.
Fig. 3. Activity assay of wild type glucarpidase (wt-CPG2) and the
three mutant enzymes using MTX as a substrate. Total protein
extracts (50 μg/ml) from cells expressing the proteins were added
to MTX (0.45mM, final concentration), and the change in absor-
bance at 320 nm recorded. The plot shows the relative activities of
WT-CPG2 (black), CPG2I100 T (dark red), CPG2T239 A (blue) and
CPG2G123S (Green) in the presence of Zn+2 relative to the control
in the absence of enzyme (red).
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mutants were determined using methotrexate as a substrate and com-
pared with the wild-type enzyme (Table 2).
3.6. Circular dichroism spectroscopy and secondary structure determination
Given the significant changes in the specific activities of the mutants
CPG2 enzymes, it was of interest to see if they also had significant
changes in their secondary structures. Accordingly, we obtained and
compared CD data in the far UV region for the wild-type and mutant
proteins to estimate such changes (Fig. 4). All three of the mutant
proteins gave more negative chiral CD signals, relative to the wild-type,
in 208–230 nm region. Overall, however, the CPG1I100 T and
CPG2G123S mutants had similar profiles to the wild type whereas the
CPGT329 A mutant was markedly different. The estimated percentage
values for the secondary structure components of the proteins were
deduced by CD deconvolution (Table 3). In keeping with the spectral
analysis, CPGT329 A was estimated to have significantly more alpha-
helical content relative to the other proteins.
The relative amounts of secondary structure in each of the proteins
was estimated by CDNN deconvolution analysis using the data shown in
Fig. 4. The average values (as percentages) of each secondary structure
component for four sets of measurements is shown.
3.7. The impact of the single point mutations on glucarpidase stability
Given the differences in secondary structure indicated by the CD
studies, we checked the predicted impact of the amino acid alterations
on the stability of the glucarpidase variants (Table 4). Three software
packages were used to predict whether the amino acid changes were
likely to stabilize or destabilize the protein structure of CPG2. Although
programs mostly predicted the changes to be destabilizing, the Site
Directed Mutator (SDM) package predicted that T329 A change would
be stabilizing.
3.8. Prediction of the hydrogen bond network of glucarpidase mutants
Visual inspection of the predicted models disclosed new hydrogen
bond network forming between the mutated amino acids and adjacent
residues as shown in the figure panel of Fig. 5.
4. Discussion
Glucarpidase, the recombinant form of CPG2, has been used for
more than two decades as a detoxifying agent for MTX and also in
targeted cancer therapies such as ADEPT. However, its usefulness in
both treatment regimens has been limited by its relatively low specific
activity and the fact that patients often develop antibodies against it
after repeated administration. In our previous study [29], we success-
fully produced two long-acting variants of glucarpidase, PEGylated
glucarpidase and HSA-fused Glucarpidase. We demonstrated that both
Table 1
The difference in activities between the wild type CPG2 and the three novel









60-210, 720-780 660 180-270 < 0.05
240-510, 660-690 150, 300-630 None < 0.01
540-630 180-270 None < 0.001
Table 2
Comparison of the kinetic parameters of the wild-type and mutant CPG2 en-
zymes using methotrexate as a substrate (± S.E.M, R2 coefficient of determi-
nation).
Enzyme Kinetic parameter
Km Vmax Kcat R2
WT CPG2 171.7 ± 65.66 52.6 ± 8.484 24.83 ± 0.9149 0.8791
CPG2 I100T 62.68 ± 10.26 55.34 ± 2.504 26.11 ± 0.3592 0.9317
CPG2 G123S 71.38 ± 13.85 57.69 ± 3.344 27.21 ± 0.4570 0.9123
CPG2 T329A 82.41 ± 15.07 57.09 ± 3.237 26.93 ± 0.4453 0.9175
Fig. 4. CD analysis in the far UV region of wt CPG2 and the three
mutants. The red, cyan, orange and dark blue curves correspond to
wild-type CPG2, CPG1I100 T, CPGT329 A, and CPG2G123S en-
zymes, respectively. The baseline corrected CD (mdeg) molar el-
lipticity [Θ] displayed more negative chiral CD signals with
shuffled proteins relative to the wild-type enzyme at the same
protein concentration (0.58mg/ml).
Table 3
Estimated secondary structure changes in the three mutants relative to the wild-
type CPG2 enzyme 1.





Parallel Beta-turn Random Total
Wild-type CPG2 34.2 8.5 8.5 16.6 32.3 100
CPG2I100T 36.2 7.6 8.2 16.2 31.5 99.6
CPG2G123S 36.4 7.5 8.1 16.0 31.7 99.7
CPG2T329A 40.7 6.6 7.2 15.5 28.5 98.5
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“biobetter” glucarpidases are less immunogenic and had prolonged
half-lives relative to the native enzyme. However, the study did not
address the question of the native enzymes relatively low specific ac-
tivity. In the present work, we used mutagenesis techniques to produce
further “biobetter” glucarpidase variants with improved activity.
Following mutagenesis of the glucarpidase gene of Pseudomonas sp.
strain RS-16 [30], approximately 73% of the clones retained enzyme
activity, as indicated by the clear zones and yellow precipitate sur-
rounding their colonies. However, there were very few that had ‘halos’
around colonies that were darker than that of the wild-type, which
would be indicative either of more active glucarpidase variants or
variants that over-produced the enzyme relative to the wild-type con-
struct. DNA sequence analysis of the three mutants taken for further
study indicated that each had a single point mutation leading to the
alteration of a single amino acid at the protein level (Supplemental Fig.
S3). The fact that only single point mutations were present suggests that
the error-prone PCR may have contributed more than the DNA shuffling
procedure to the production of these particular mutants. Alternatively,
it is possible that combining two or more individual mutations into a
single gene may have resulted in mutant enzymes with little or no
enzyme activity.
The three mutant enzymes, named CPG2 I100 T, CPG2 G123S, and
CPG2 T329 A, were then characterized in greater detail. In keeping with
their colony phenotypes, each had a higher specific activity in enzyme
assays, and this was supported by the results of studies to determine
their kinetic parameters. Specifically, the three mutants had higher
substrate affinity as shown by their lower Km values relative to the wild-
type enzyme (Table 2). It remains to be seen if combining two or more
of the mutations into the same CPG2 gene results in a further increase in
enzyme activity.
Having established that the mutants had increased enzyme activity
against the substrate MTX, it was then of interest to determine the
extent to which their structures had been perturbed. Accordingly, we
carried out a CD study to check for alterations in secondary structure,
and also analyzed their predicted amino acid sequences using programs
designed to predict changes in protein stability. For two of the mutants,
CPG2 I100 T and CPG2 G123S, the alterations in secondary structure
appear to be modest although it is likely that they are slightly desta-
bilizing.
The analysis of the three web servers to predict the effect of a single
mutant [22–24], the prediction shows a higher destabilizing effect in
position 100 and 123 compared to 329 of the three mutants. In contrast,
CD analysis of the third mutant, CPG2 T329 A, suggests that it has a
marked increase in alpha-helical content, which, interestingly, might
even lead to a modest increase in its structural stability, as indicated by
analysis with the SDM software package (Table 4).
It has previously been shown [31] that amino acids in a protein that
is involved in enzyme catalysis are not optimized for stability. Thus,
replacement of specific residues may reduce the activity of an enzyme
but concomitantly increase its stability. Alternatively, the replacement
of residues involved in protein stability could lead to higher enzyme
activity. The results presented in this work are consistent with these
findings. The three randomly produced glucarpidase mutation sub-
stitution, I100 T, G123S and T329 A, increased the enzyme activity in
each case but are predicted to decrease the stability of each mutant
(Fig. 3, Table 4).
Our study may also suggest the involvement of the isoleucine, gly-
cine and alanine at positions 100, 123 and 329, respectively, in glu-
carpidase catalysis. It has previously been shown that [32] proteins
with specific sites known as flexibility hotspots are important for both
binding and stability.
The predicted structure (Fig. 5) shows that in the two mutations,
I100 T and G123S, hydrophobic and neutral side chains respectively,
are replaced replace with a polar functional group. As previously
Table 4
Predicted stabilities of the mutant CPG2 enzymes.






mCSM [22] −2.127Kcal/mol (destabilizing) −2.205 Kcal/mol (destabilizing) −0.535 Kcal/mol (destabilizing)
SDM [23] −2.66 Kcal/mol (destabilizing) −2.23 Kcal/mol (destabilizing) 0.16 Kcal/mol (stabilizing)
DUET [24] −2.34 Kcal/mol (destabilizing) −2.246Kcal/mol (destabilizing) −0.283 Kcal/mol (destabilizing)
Fig. 5. Figure panel is showing the modelled
prediction of hydrogen bond network fol-
lowing point mutation in the various mutants.
(A) Cartoon representation of chain A of glu-
carpidase. Red arrows indicate where the
single point mutations were made. (B)
Compared to the native type, the mutant
I100 T acquires a new hydrogen bond between
the hydroxyl group of threonine and the car-
boxyl group of Leu-97. (C) The mutant G123S
forms a hydrogen bond with Ile-118 similarly
to the unmutated form but interacts with Ala-
119 and loses the hydrogen bond with Val-127.
(D) On the contrary, in mutant T329 A no extra
hydrogen bonds with neighbored residues
were observed.
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observed [33], only certain amino acids show a specific propensity to
become part of an alpha helix [33]: according to the proposed scale, the
helical penalty of threonine and serine are 0.66 Kcal/mol and 0.50
Kcal/mol. Such thermodynamic penalties can be related to steric cla-
shes and the formation of new hydrogen bonds, as we propose in our
models. The substitution with such amino acids can therefore lead to a
destabilization to the wild type, and this reinforces the validity of the
model calculated for the I100 T and G123S which were found to be
more active to cleave the methotrexate compared to T329 A.
Further information on these points will probably require X-Ray
crystallographic or NMR studies on the mutants. Such studies might
also open a rational pathway for further changes to produce other
variants with different features.
5. Conclusion
In this study, we produced three novel glucarpidase variants with
improved enzyme activity. The mutants may be beneficial in MTX de-
toxification and may also have applications in targeted cancer strategies
such as ADEPT.
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